Dor

DRUG2 trials

Sponsors

Karolinska University Hospital, Merck Sharp & Dohme LLC

Conditions

AchalasiaHIV-1 Infection

Phase 3

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

CompletedNCT04233216

Merck Sharp & Dohme LLCHIV-1 Infection

Start: 2020-03-18End: 2023-11-01Updated: 2024-12-27

Unknown Phase

A Prospective Study Comparing Two Reconstructive Operation Techniques After Myotomy of Achalasia

CompletedNCT01933373

Karolinska University HospitalAchalasia

Start: 2007-05-31End: 2012-12-31Updated: 2013-09-02

Related Papers

Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial.

2025-10-01

Toupet versus Dor as a procedure to prevent reflux after cardiomyotomy for achalasia: Results of a randomised clinical trial

International Journal of Surgery2014-06-0265 citations